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Introduction
============

Mutations of the *nucleophosmin* (*NPM*) gene occur in ∼35% of acute myelogenous leukemias (AMLs) and are mutually exclusive with the major AML-associated genetic abnormalities, which suggests that they represent an initiating event in myeloid leukemogenesis ([@bib10]). The underlying mechanisms, however, remain unknown.

NPM is a ubiquitously expressed nucleolar protein that functions as a molecular chaperone ([@bib24]) and shuttles between the nucleus and cytoplasm ([@bib3]). It is part of a high--molecular weight complex and physically interacts with many cellular proteins including p53 ([@bib4]), Mdm2 ([@bib20]), and Arf ([@bib18]). NPM binds Arf and protects it from degradation ([@bib19]). In *NPM−/−* cells, the Arf protein looses its nucleolar localization and becomes markedly unstable, which suggests that NPM is required for correct localization and stability of Arf ([@bib5]). This function of NPM is lost in mutant NPM (NPMmut), which contains a de novo nuclear export signal and mainly localizes in the cytoplasm ([@bib22]). NPMmut competes with wild-type (WT) NPM for Arf binding and targets Arf to the cytoplasm, where it becomes more susceptible to degradation ([@bib6]).

Preliminary evidence suggests, however, that NPM controls other intracellular pathways that negatively regulate cell proliferation. In *NPM−/−* embryos, cells proliferate more actively, accumulate DNA damage, and undergo p53-dependent apoptosis ([@bib5]), a picture that is reminiscent of the DNA damage response induced by oncogene expression in primary cells ([@bib2]). *NPM−/−* cells also show aberrant mitotic figures with multiple centrosomes ([@bib14]) and are more susceptible to transformation by activated oncogenes such as Myc and Ras ([@bib5]). Consistently, *NPM*± mice show accelerated Myc-induced lymphomagenesis ([@bib14]). We report here that NPM and its AML-associated mutant regulate the stability of the c-Myc protein.

Results and discussion
======================

We initially analyzed levels of c-Myc in lysates from *NPM−/−* and WT whole embryos. Western blotting (WB) revealed a marked increase of the c-Myc protein in the *NPM−/−* samples ([Fig. 1 a](#fig1){ref-type="fig"}, left). Levels of *c*-*myc* mRNA, instead, were equivalent in the two samples ([Fig. 1 a](#fig1){ref-type="fig"}, right), which suggests that the increased levels of c-Myc protein in the *NPM−/−* embryos were caused by enhanced protein stability. Accordingly, we observed a moderate increase in mRNA expression for several c-Myc target genes in *NPM−/−* embryos ([Fig. 1 b](#fig1){ref-type="fig"}).

![**NPM regulates c-Myc protein stability.** (a, left) WB analysis of two NPM WT (Nos. 1 and 2) and knockout (KO; Nos. 2 and 3) embryos at 10.5 d post coitum ([@bib5]). (right) *c-Myc* mRNA levels in the same embryos evaluated by QPCR (results are normalized against WT samples). (b) Expression of c-Myc target genes analyzed by QPCR using mRNA from WT and NPM KO embryos. Expression was standardized with ubiquitin and normalized against the control WT RNAs. (c) c-Myc protein levels (left) and *c-Myc* mRNA levels (right) in *p53−/−* and dKO MEFs. (d) QPCR of anti c-Myc ChIP. The percentage of DNA bound to c-Myc was calculated as described previously ([@bib12]). (e) QPCR analysis of c-Myc target genes at 8 h after serum treatment. Results analyzed as in panel b. (f) c-Myc protein level in *p53−/−* and dKO MEFs. Cells were treated with CHX and harvested at the indicated time points. (g, left) c-Myc protein levels in *p53−/−* and dKO MEFs infected with retroviruses expressing the GFP-NPM1 protein (+NPM) or control retroviruses. (middle) WB analysis of the same cells during serum starvation and upon serum release. (right) QPCR analysis of c-Myc target gene expression after serum treatment (8 h) as in panel d. (h) c-Myc protein level in *p53−/−*, dKO, and dKO + GFP-NPM MEFs as described in panel f. Data represent the mean of three determinations ± SEM.](jcb1820019f01){#fig1}

We then examined c-Myc levels in cultured fibroblasts (mouse embryonic fibroblasts \[MEFs\]) from double knockout *NPM−/−;p53−/−* embryos (dKO) and, as controls, MEFs from *p53−/−* embryos. *NPM−/−* MEFs, in fact, do not grow in culture due to the accumulation of DNA damage and rapid acquisition of a p53-dependent senescence-like phenotype ([@bib5]). c-Myc protein was elevated in dKO MEFs as compared with the *p53−/−* cells ([Fig. 1 c](#fig1){ref-type="fig"}, left) in the absence of significant variations of the amount of *c*-*myc* transcripts ([Fig. 1 c](#fig1){ref-type="fig"}, right). dKO MEFs also showed increased binding of c-Myc to target promoters, as assayed by chromatin immunoprecipitation (ChIP; [Fig. 1 d](#fig1){ref-type="fig"}), and an increased induction of c-Myc target genes after serum stimulation of starved cells ([Fig. 1 e](#fig1){ref-type="fig"}). To measure the half-life of the c-Myc protein, dKO and control cells were treated with cycloheximide (CHX; an inhibitor of de novo protein synthesis widely used to measure c-Myc protein half-life; [@bib25]) and lysed at different time points to follow c-Myc protein degradation. As an internal control, we monitored expression of γ-tubulin ([@bib5]). WB in the *p53−/−* MEFs confirmed that c-Myc is an unstable protein with a half-life of ∼20 min ([@bib13]). In the dKO cells, instead, the c-Myc protein appeared to be more stable, with a calculated half-life of ∼40 min ([Fig. 1 f](#fig1){ref-type="fig"}). It appears, therefore, that NPM regulates stability of the c-Myc protein. To confirm the NPM dependency, we reconstituted NPM expression in dKO cells and measured levels of c-Myc protein, c-Myc protein stability, and c-Myc target gene expression. Notably, NPM reexpression in *NPM−/−* MEFs reduced the half-life of the c-Myc protein ([Fig. 1 g](#fig1){ref-type="fig"}, left; and [Fig. 1 h](#fig1){ref-type="fig"}), its steady-state and serum-stimulated levels ([Fig. 1 g](#fig1){ref-type="fig"}, middle), and expression of c-Myc target genes after serum stimulation ([Fig. 1 g](#fig1){ref-type="fig"}, right). Finally, to investigate the effects of p53 on c-Myc expression, we evaluated levels of *c-myc* mRNA/protein and c-Myc protein stability in WT and *p53*-null MEFs. As shown in Fig. S1 a (available at <http://www.jcb.org/cgi/content/full/jcb.200711040/DC1>), a lack of p53 led to increased levels of *c-Myc* mRNA and protein, as previously described ([@bib16]). Notably, however, the stability of the c-Myc protein was the same in the two cell types (Fig. S1 b). Down-regulation of NPM expression by siRNA induced up-regulation of c-Myc protein levels, but not of the corresponding mRNA, in both the WT and *p53−/−* MEFs (Fig. S2 c), thus indicating that the effect of NPM silencing on c-Myc protein is p53 independent.

c-Myc is degraded through the ubiquitin--proteasome pathway ([@bib28]), and its ubiquitination is controlled by two different F-box proteins, Fbw7 and Skp2 ([@bib15]). Three isoforms of Fbw7 have been described that differ in their intracellular localization: Fbw7α (nuclear diffuse), Fbw7β (cytoplasmic), and Fbw7γ (nucleolar). Although all three Fbw7 isoforms have the potential to bind it, preliminary evidence suggests that c-Myc is prevalently degraded by Fbw7γ ([@bib25]). Because NPM localizes to the nucleolus (where it colocalizes with Fbw7γ; Fig. S1 d), we investigated whether the Fbw7γ isoform is involved in the regulation of c-Myc stability by NPM. The HA-tagged version of Fbw7γ was overexpressed in dKO or p53−/− control cells previously engineered with a Myc--estrogen receptor fusion protein (Myc-ER) whose activity is induced by treatment with 4-hydroxytamoxifen (4-OHT). Treatment of *p53−/−* control cells with OHT rapidly induced nuclear translocation of Myc-ER (not depicted), its stabilization ([Fig. 2 a](#fig2){ref-type="fig"}), and binding to target promoters ([Fig. 2 b](#fig2){ref-type="fig"}). Overexpression of Fbw7γ reduced Myc-ER protein stabilization and promoter occupancy in *p53−/−* cells ([Fig. 2, a and b](#fig2){ref-type="fig"}) but had no effects in dKO cells ([Fig. 2, a and b](#fig2){ref-type="fig"}). The same experiments were repeated in the dKO and *p53−/−* parental cells. Overexpression of Fbw7γ slightly yet consistently reduced levels of endogenous c-Myc protein and c-Myc occupancy at target promoters in the p53−/− cells but not in dKO cells ([Fig. 2, c and d](#fig2){ref-type="fig"}). It appears, therefore, that NPM expression is critical for the ability of Fbw7γ to regulate c-Myc protein levels.

![**NPM is required for Fbw7γ activity.** (a) WB analysis in *p53−/−* and dKO MEFs infected with Myc-ER and, where indicated (+), HA-Fbw7γ--expressing retroviruses. Cells were treated with 4-OHT for the indicated hours or left untreated (0 h). (b) QPCR of anti--c-Myc ChIP on target promoters (as indicated) after 4-OHT treatment of the same cells as in panel a. (c) WB analysis in *p53−/−* and dKO MEFs infected with retroviruses expressing HA-Fbw7γ (+) or control retroviruses (−) as indicated. c-Myc levels have been calculated by densimetric analysis, normalizing band intensity to actin and control *p53−/−* cells. (d) QPCR analysis of anti c-Myc ChIP on target promoters (as indicated) of the same cells as in panel c. (e) dKO MEFs were cotransfected with plasmids expressing NPM1 and flag-Fbw7γ (left), flag-Fbw7α (middle), and flag-Fbw7β (right). Total lysates and immunoprecipitates were blotted with antibodies against NPM (NPMa) or anti-flag. (f) GST pull-down assay using in vitro translated ^35^S-labeled Fbw7γ or Fbw7α and equal amounts of GST or GST-NPM proteins. Data represent the mean of three determinations ± SEM.](jcb1820019f02){#fig2}

We than analyzed whether NPM interacts physically with Fbw7γ and affects the localization and expression levels of Fbw7γ. Coimmuprecipitation experiments revealed that NPM forms a complex in vivo with ectopically expressed tagged Fbw7γ ([Fig. 2 e](#fig2){ref-type="fig"}, left). The interaction is likely to be direct, as recombinant GST-NPM bound in vitro translated Fbw7γ ([Fig. 2 f](#fig2){ref-type="fig"}). No interactions were detected between NPM and Fbw7α ([Fig. 2, e and f](#fig2){ref-type="fig"}) or β ([Fig. 2 e](#fig2){ref-type="fig"}).

Immunofluorescence (IF) analysis ([Fig. 3 a](#fig3){ref-type="fig"}, top) showed that Fbw7γ was concentrated in the nucleoli of *p53−/−* cells, as expected. In dKO MEFs, the nucleolar localization of Fbw7γ was lost, replaced by a diffuse nuclear staining. These alterations in localization were specific for the Fbw7γ isoform because Fbw7α and Fbw7β showed unchanged localization patterns in dKO and control cells ([Fig. 3 a](#fig3){ref-type="fig"}, bottom left and bottom right). Fbw7γ levels in the dKO MEFs were also consistently lower than in the control *p53−/−* MEFs ([Fig. 3 b](#fig3){ref-type="fig"}, left), whereas mRNAs were comparable ([Fig. 3 b](#fig3){ref-type="fig"}, right). CHX treatment revealed that the half-life of Fbw7γ in *p53−/−* MEFs was ∼80 min but was reduced in the dKO to ∼30 min ([Fig. 3 c](#fig3){ref-type="fig"}). The half-life of Fbw7γ protein was not influenced by expression of p53 (Fig. S1 e). Accordingly, Fbw7γ−dependent ubiquitination of c-Myc was reduced in NPM-null cells ([Fig. 3 d](#fig3){ref-type="fig"}). Finally, we analyzed the ability of Fbw7γ to inhibit c-Myc--dependent transformation. Overexpression of Fbw7γ induced a significant attenuation of the transformed phenotype in OHT-treated *p53−/−*;Myc-ER cells, as shown by their reduced ability to form colonies in semisolid medium ([Fig. 3 e](#fig3){ref-type="fig"}). Overexpressed Fbw7γ, instead, had no effect on OHT-treated dKO;Myc-ER cells ([Fig. 3 e](#fig3){ref-type="fig"}). In summary, NPM positively regulates the nucleolar localization and stability of the Fbw7γ protein and is essential for the ability of Fbw7 to promote c-Myc degradation and limit cell transformation. The effect of NPM on c-Myc protein stability appears to be specifically exerted through Fbw7γ, as we found no effects of NPM on expression and localization of Skp2 (Fig. S1 f).

![**NPM is required Fbw7γ nucleolar localization and stability.** (a) IF analysis of Fbw7γ (top), Fbw7α (bottom left), and Fbw7β (bottom right) localization in p53−/− and dKO MEFs transiently transfected with the corresponding flag-Fbw7 constructs (green staining). Anti-fibrillarin staining (red) is shown as a marker for nucleoli. Bars, 10 μm. (b, left) WB analysis in *p53−/−* and dKO MEFs infected with retroviruses expressing HA-Fbw7γ (+) or control retroviruses (−) as indicated. (right) *Fbw7γ* mRNA levels in *p53−/−* and dKO MEFs. (c) HA-Fbw7γ protein stability in *p53−/−* and dKO MEFs. Cells were treated with CHX and harvested at the indicated time points. (d) Effects of Fbw7γ expression on Myc ubiquitination in *p53−/−* and dKO cells. *p53−/−* (lanes 1--3) and dKO (lanes 4--6) MEFs were transfected with expression vectors for HA-tagged ubiquitin and flag-tagged Fbw7γ, as indicated. Cell lysates were IPed with an anti-Myc antibody and blotted with anti-HA (to identify ubiquitinated myc; UB-myc) and anti-Myc (as control) antibodies. Levels of flag-Fbw7γ in the input were analyzed with an anti-flag antibody. (e) Methylcellulose colony assay of *p53−/−* and dKO MEFs expressing Myc-ER protein and infected with control (EV) or HA-Fbw7γ--expressing retroviruses. 4-OHT was added every 3 d; colonies were counted after 15 d. Data represent the mean of three determinations ± SEM. \*, P \< 0.045.](jcb1820019f03){#fig3}

c-Myc is frequently overexpressed in human cancers ([@bib1]). c-Myc protein and/or RNA are also frequently overexpressed in AMLs, though the underlying molecular mechanisms are unknown ([@bib17]). We thus investigated whether expression of the AML-associated mutant of NPM leads to increased c-Myc expression. Ectopic expression of NPMmut in WT MEFs increased the steady-state levels of the c-Myc protein in the absence of significant variations of the amount of *c-Myc* transcripts ([Fig. 4 a](#fig4){ref-type="fig"}) and the expression of several Myc-target genes ([Fig. 4 b](#fig4){ref-type="fig"}). These effects were maintained in *Arf−/−* MEFs ([Fig. 4 e](#fig4){ref-type="fig"}) and were thus independent on the presence of Arf in the nucleolus or its interaction with Myc ([@bib26]).

![**Mutant NPM stabilizes the c-Myc protein.** (a, left) WB analysis in WT and *NPM±* MEFs infected with retroviruses expressing NPMmut (Mut) or control (EV) retroviruses. (right) *c-Myc* mRNA levels in the same cell. (b) QPCR analysis of the indicated c-Myc target genes. (c, left) Growth curves of *NPM±* MEFs infected with retroviruses expressing NPMmut or control (EV) retroviruses. 10^4^ cells were plated in presence of 10% serum (high serum) or 0.5% serum (low serum) as indicated. (right) The percentage of apoptosis in the same cells maintained in low serum culture conditions for 24 h. (d) QPCR analysis of the indicated c-Myc target genes in *NPM±* MEFs infected with EV or NPMmut retroviruses. (e, left) WB analysis in *ARF−/−*, *p53−/−*, and dKO MEFs infected with retroviruses expressing NPMmut (mut) or control (EV) retroviruses. (right) *c-Myc* mRNA levels in the same samples. (f) QPCR analysis of the indicated c-Myc target genes in the same cells as in panel e. Data represent the mean of three determinations ± SEM.](jcb1820019f04){#fig4}

To gain evidence that this effect of NPMmut on c-Myc is biologically relevant, we analyzed growth of fibroblasts ectopically expressing NPMmut. Overexpression of c-Myc induces DNA damage ([@bib9]) and, in primary fibroblasts, a p53-dependent cellular checkpoint mainly characterized by a reduction of cell proliferation; when cells are grown in low serum, it also induces apoptosis ([@bib30]). Ectopic expression of the NPMmut in MEFs induced no modifications of Arf protein levels (Fig. S1 g), it increased the levels of γH2AX (a marker of DNA damage) and phosphorylated p53 (Fig. S1 g), decreased the proliferation rate, and, in low serum conditions, induced massive apoptosis ([Fig. 4 c](#fig4){ref-type="fig"}). Together, these results suggest that apoptosis induced by NPMmut expression follows c-Myc stabilization, induction of DNA damage, and activation of p53.

We then investigated whether the effect of NPMmut on c-Myc stability is mediated by Fbw7γ. The ability of overexpressed Fbw7γ to down-regulate Myc-ER levels was completely lost in the presence of NPMmut expression ([Fig. 5 a](#fig5){ref-type="fig"}). Moreover, in the presence of NPMmut, levels of Fbw7γ protein were almost undetectable without changes of its mRNA ([Fig. 5 a](#fig5){ref-type="fig"}). Treatment of the same cells with the MG132 proteasome inhibitor for 2 h was sufficient to reconstitute Fbw7γ expression at levels similar to those observed in control cells without NPMmut ([Fig. 5 b](#fig5){ref-type="fig"}). It appears, therefore, that NPMmut induces destabilization of Fbw7γ and, as a consequence, stabilization of c-Myc.

![**Mutant NPM delocalizes and destabilizes Fbw7**γ. (a, left) WB analysis in *p53−/−*;Myc-ER cells infected with empty (No. 2) or HA-Fbw7γ-expressing (No. 4) retroviruses. HA-Fbw7γ--infected cells were reinfected with empty or NPMmut-expressing lentiviruses (also expressing GFP as marker). Cells were treated for 2 h with 4-OHT (Nos. 2--4). (right) QPCR analysis of *Fbw7γ* mRNA levels in samples Nos. 3 and 4. Data represent the mean of three determinations ± SEM. (b) WB analysis in the same cells as in panel a. Cells were or were not treated with MG132 for 2 h, as indicated. (c) dKO MEFs were cotransfected with plasmids expressing flag-Fbw7γ and NPMmut or the empty vector, as indicated. Total lysates and IPs were blotted with antibodies against NPMmut or the flag epitope. (d) IF analysis of *p53−/−* MEFs infected with GFP-NPMmut-- and flag-Fbw7γ (red staining)-expressing constructs. A merge of the NPMmut, Fbw7γ, and DAPI staining is also shown. Bar, 10 μm. (e) Nucleus--cytoplasm fractionation in *p53−/−* MEFs expressing flag-Fbw7γ infected with GFP-NPMmut or control (EV) retroviruses. Total cell lysates (T) or cellular fractions (C, cytoplasm; N, nucleus) were analyzed by WB as indicated. (f) The same cells as in panel e were or were not treated with 1 μM LMB or MG132 for 3 h, as indicated. Expression of Fbw7γ was analyzed by WB on total cells lysates using anti-flag antibodies.](jcb1820019f05){#fig5}

Finally, we investigated the mechanism through which NPMmut affects Fbw7γ protein stability. Coimmunoprecipitation experiments in *NPM*-deficient MEFs revealed that NPMmut is able to form a complex with Fbw7γ both in the absence ([Fig. 5 c](#fig5){ref-type="fig"}) or presence (not depicted) of WT NPM. IF analysis of the intracellular localization of Fbw7γ in *p53−/−* and dKO showed that expression of NPMmut causes, in both cell types, a partial displacement of Fbw7γ from the nucleus to the cytoplasm ([Fig. 5 d](#fig5){ref-type="fig"} and Fig. S2 a, available at <http://www.jcb.org/cgi/content/full/jcb.200711040/DC1>). These results were confirmed by WB analysis of the levels of Fbw7γ in nuclear and cytoplasmic fractions of *p53−/−* and dKO cells in the presence or absence of NPMmut expression ([Fig. 5 e](#fig5){ref-type="fig"} and Fig. S2 b). The ability of NPMmut to delocalize Fbw7γ and to form a complex in cells also in the presence of the WT NPM suggest that NPMmut competes with the WT protein to bind Fbw7γ. Consistently, we observed that up-regulation of c-Myc protein levels ([Fig. 4 a](#fig4){ref-type="fig"}) and Myc-target gene expression ([Fig. 4 d](#fig4){ref-type="fig"}) by NPMmut were facilitated in NPM+/− MEFs, which carry reduced levels of NPM ([@bib14]).

To investigate if the cytoplasmic displacement of Fbw7γ correlates with its degradation, we analyzed levels of the Fbw7γ protein upon treatment of *p53−/−* and dKO cells with the nuclear-export inhibitor leptomycin B (LMB) as compared with treatment with the proteasome inhibitor MG132. As shown in [Fig. 5 f](#fig5){ref-type="fig"} and Fig. S2 c, LMB and MG132 increased the levels of Fbw7γ to the same extent in both cell types. However, despite the fact that NPMmut induced degradation of Fbw7γ in dKO cells ([Fig. 4 e](#fig4){ref-type="fig"}), it did not increase c-Myc protein levels in the same cells, which is consistent with the observation that, in the absence of WT NPM, the function of Fbw7γ is lost, regardless of its nuclear or cytoplasmic localization ([Fig. 2, a--c](#fig2){ref-type="fig"}). These data are consistent with the reported chaperone activity of WT NPM in maintaining the proper folding and activity of its interactors ([@bib29]). In summary, we observed that expression of NPMmut induces delocalization and accelerated degradation of Fbw7γ also in the absence of the WT NPM protein, thus demonstrating that the effect of the mutant NPM on Fbw7γ is direct. Furthermore, because LMB treatment induced nuclear relocalization of NPMmut and Fbw7γ and restoration of physiological levels of Fbw7γ protein, aberrant cytoplasmic localization of the NPMmut appears critical for the degradation of Fbw7γ.

In conclusion, our findings demonstrate that NPM regulates c-Myc protein stability through its effect on the γ-isoform of the F-box E3 ubiquitin ligase Fbw7. They are consistent with a model whereby NPM binds directly to Fbw7γ and serves as a molecular chaperone to ensure its proper folding, nucleolar localization, and to prevent its degradation. This effect of NPM on Fbw7γ is relevant for the regulation of one of its substrates, c-Myc, which, in fact, accumulates in the absence of NPM.

The effect of NPM on Fbw7 regulation, however, might be more complex. Other intracellular proteins are also Fbw7-substrates, including Notch, cyclin E, and c-Jun ([@bib23]). Because NPM does not regulate the Fbw7α and Fbw7β isoforms, it might allow regulation of Fbw7γ-specific substrates or the nucleolar site of degradation of Fbw7-common substrates. Close inspection of the regulation of Notch, cyclin E, and c-Jun protein stability and function in *NPM−/−* cells might help to elucidate this question.

The leukemia-associated mutant of NPM interacts with Fbw7γ and delocalizes it to the cytoplasm, thus favoring its degradation. As a consequence, c-Myc protein levels are increased in cells expressing the NPMmut. Notably, c-Myc protein is frequently overexpressed in AMLs and stabilized in several leukemia cell lines ([@bib17]), and c-Myc overexpression favors myeloid leukemogenesis in mouse models ([@bib21]). Thus, the pathway of c-Myc degradation is relevant for human cancer, which suggests that elevated c-Myc protein expression might contribute to leukemogenesis in the NPMmut AMLs.

Oncogene-induced hyperproliferation activates an Arf- and p53-dependent intracellular checkpoint that leads to cell cycle arrest or apoptosis ([@bib8]). Remarkably, the NPMmut also favors Arf degradation, which suggests that in AMLs, a single genetic mutation might have the double effect of activating proliferation and attenuating the resulting checkpoint response. This would probably result in accelerated leukemogenesis and reduced pressure for accumulation of further genetic abnormalities. Interestingly, AMLs with NPMmut usually have normal karyotypes ([@bib10]).

Materials and methods
=====================

qChIP and quantitative PCR (QPCR) analysis
------------------------------------------

MEFs were grown and processed for qChIP analysis as described previously ([@bib12]) using anti-Myc (N-262; Santa Cruz Biotechnology, Inc.) antibodies. Immunoprecipitated DNA from ∼1 × 10^7^ cell equivalents was resuspended in 300 μl of 10 mM Tris at pH 8.0. Real-time PCR was performed with 6 μl of DNA per reaction and 200 nM of primers, diluted in a final volume of 20 μl of SYBR Green reaction mix (PerkinElmer). Data represent the mean of three determinations ± SEM. A list of the used primers is shown in Table S1 (available at <http://www.jcb.org/cgi/content/full/jcb.200711040/DC1>).

Total RNA was extracted from MEFs with an RNAeasy MiniKit (QIAGEN), including a DNase treatment before elution from the column, and processed as described previously ([@bib12]). Each PCR reaction contained 10 ng of cDNA template and primers at a concentration of 800 nM in a final volume of 20 μl of SYBR Green reaction mix. Data represent the mean ± SEM of three determinations for each gene. A list of the used primers is shown in Table S1.

Cell culture, transfection, and infection
-----------------------------------------

MEFs, Phoenix, and 293T packaging cell lines were cultured at 37°C and 5% CO~2~ in DME supplemented with 10% fetal bovine serum. Empty or recombinant retroviral or lentivirus vectors were transfected into phoenix or 293T packaging cell lines, respectively, and after 48 h, the supernatants were used to infect target cells. Transient transfections were performed using the standard calcium phosphate precipitate method for Phoenix, 293T, and Fugene 6 (Roche) for MEFs.

Immunoblotting, immunoprecipitation (IP), and IF
------------------------------------------------

WB, IP, and IF experiments were performed as described previously ([@bib4]). All protein total lysates for WB analysis were performed in Laemmli buffer. The primary antibodies used for WB were: monoclonal anti-NPM (NPMa that recognizes both WT and mutant NPM, and NPMc that recognizes only the WT NPM1 isoform; [@bib7]); monoclonal anti-NPMmut specific (homemade according to the protocol described in [@bib27]), anti-Myc (provided by S. Hann, Vanderbilt University School of Medicine, Nashville, TN), anti-flag (Sigma-Aldrich), monoclonal anti-HA (Covance), anti-actin (Sigma-Aldrich), anti-tubulin (Santa Cruz Biotechnology, Inc.). The primary antibodies used for IPs were: monoclonal anti-NPM (Invitrogen), monoclonal anti-NPMmut, monoclonal anti-flag M2 (Sigma-Aldrich), anti-fibrillarin (Santa Cruz Biotechnology, Inc.), and monoclonal anti-HA (Covance). Secondary antibodies conjugated to FITC or Cy3 fluorochromes were used for immunofluorescence.

Images were acquired at room temperature using a camera (C4742-95; Hamamatsu) on a microscope (BX61; Olympus) with 60× 1.40 NA oil objective lenses (Olympus). The acquisition software was Cell\^F (Olympus).

Plasmids
--------

*Fbw7α*, *Fbw7β*, and *Fbw7γ* flag-tagged plasmids were provided by B. Clurmann (Fred Hutchinson Cancer Research Center, Seattle, WA). *Fbw7α* and *Fbw7γ* cDNAs were subcloned in the pCDNA3.1 mammalian expression vector (Invitrogen). *Fbw7γ* was also subcloned in the pBabe-flag-HA retroviral vector. The mutated form of *NPM* (NPMmut) was cloned in the pRRLsin.hPGK.IRES.EGFP.Wpre vector ([@bib11]) using BamH1 restriction sites. The plasmid expressing HA-ubiquitin was kindly provided by S. Polo (Istituto FIRC di Oncologia Molecolare \[IFOM\], Milan, Italy).

Apoptosis assay
---------------

Cells were harvested and double fixed in 1% formaldehyde and then cold ethanol. After permeabilization in 0.1% Triton X-100 for 10 min, cells were stained with anti-cleaved caspase3 antibody (Cell Signaling Technology), washed, and incubated with cy5-conjugated secondary antibody. The percentage of positive cells was evaluated by FACS analysis.

Nuclear and cytoplasmic fractionation
-------------------------------------

MEFs were washed twice in ice-cold hypotonic buffer (20 mM Hepes, pH 7, 5 mM potassium-acetate, 0.5 mM MgCl2, and 0.5 mM DTT) supplemented with protease inhibitors, and then swollen on ice for 10 min. After buffer removal, cells were collected by scraping and disrupted by vigorous pipetting. The integrity of nuclei was checked with the microscope after trypan blue staining. Nuclei were pelleted at 4,000 rpm for 5 min, and supernatants were stored as cytoplasmic fraction. The nuclear fraction was washed twice with hypotonic buffer and then lysed in Laemmli buffer. Equal volumes of nuclear and cytosolic fractions were loaded on an SDS-polyacrylamide gel for WB analysis.

Statistical analysis
--------------------

Statistical significance was evaluated by nonparametric Mann-Whitney *U* test (Wilcoxon-Kruskal Wallis) to analyze variables that were not normally distributed. Significance was defined at P \< 0.05 (two-tailed test).

Online supplemental material
----------------------------

Fig. S1 shows control experiments regarding the role of p53 in regulating c-Myc and Fbw7γ half-lives, the role of NPM in controlling Skp2 protein localization and stability, and the expression levels of different proteins upon NPMmut expression in MEFs. Fig. S2 shows the effect of NPMmut expression in dKO MEFs on Fbw7γ localization and stability. Table S1 shows all the primers used in the QPCR experiments. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200711040/DC1>.
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